Breaking News, Collaborations & Alliances

Vertex Obtains Exclusive License to TreeFrog’s C-Stem Technology

Aims to optimize production of its cell therapies for type 1 diabetes.

Author Image

By: Charlie Sternberg

Associate Editor

Vertex Pharmaceuticals has obtained an exclusive license to TreeFrog Therapeutics’ proprietary cell manufacturing technology, C-Stem, to optimize production of its cell therapies for type 1 diabetes (T1D). TreeFrog and Vertex will collaborate to scale-up TreeFrog’s process to produce and amplify cells for Vertex’s T1D therapies.   TreeFrog’s proprietary technology platform, C-Stem, is designed to mimic the natural microenvironment, allowing cells to grow exponentially i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters